Clinical efficacy of radiofrequency ablation in treatment of colorectal cancer with liver metastasis in elderly patients

doi:10.3877/cma.j.issn.2095-3232.2021.03.015

Abstract

Abstract:

Objective

To evaluate the safety and efficacy of radiofrequency ablation (RFA) in the treatment of colorectal cancer with liver metastasis in elderly patients.

Methods

Clinical data of 87 elderly patients with colorectal cancer with liver metastasis admitted to the Fourth Affiliated Hospital of Henan University of Science & Technology from January 2013 to June 2017 were retrospectively analyzed. The informed consents of all patients were obtained and the local ethical committee approval was received. Among them, 55 patients were male and 32 female, aged from 70 to 78 years, with a median age of 74 years. According to the treatment methods of liver metastases, all patients were divided into the RFA group (n=48) and resection group (n=39). Perioperative conditions of patients between two groups were observed. The operation time and intraoperative blood loss were statistically compared between two groups by t test. The incidence of complications and recurrence rates were statistically compared between two groups by using Chi-square test. Survival analysis was performed by Kaplan-Meier method and Log-rank test.

Results

In the RFA group, the average operation time, intraoperative blood loss and length of postoperative hospital stay were (46±10) min, (29±9) ml and (2.5±0.3) d, respectively, significantly less than (126±25) min, (301±80) ml and (7.3±1.8) d in the resection group (t=-5.317, -7.233, -12.672; P<0.05). The incidence of complications in the RFA group was 6%(3/48), significantly lower than 23%(9/39) in the resection group (χ²=5.124, P<0.05). The median survival time was 40 months in the RFA group, and 43 months in the resection group, where no significant difference was observed between two groups (χ²=1.687, P>0.05).

Conclusions

RFA is a safe and reliable treatment for the elderly patients with colorectal cancer and liver metastasis, which can achieve equivalent efficacy to surgery.

Key words: Ablation techniques, Hepatectomy, Colorectal neoplasms, Neoplasm metastasis

Qingbing Wang, Yanjun Wang, Yong Zhang, Zhiling Shen, Jian'an Xiao. Clinical efficacy of radiofrequency ablation in treatment of colorectal cancer with liver metastasis in elderly patients[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2021, 10(03): 306-309.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2021.03.015

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2021/V10/I03/306

Figures/Tables 3

References 21

[1]	Raoof M, Haye S, Ituarte PHG, et al. Liver resection improves survival in colorectal cancer patients: causal-effects from population level instrumental variable analysis[J]. Ann Surg, 2019, 270(4):692-700.
[2]	中华医学会外科学分会胃肠外科学组，中华医学会外科学分会结直肠肛门外科学组，中国抗癌协会大肠癌专业委员会, 等. 结直肠癌肝转移诊断和综合治疗指南(2016)[J]. 中国实用外科杂志, 2016, 36(8):858-869.
[3]	庹吉妤，张敏，郑荣寿, 等. 中国2014年胆囊癌发病与死亡情况分析[J]. 中华肿瘤杂志, 2018, 40(12):894-899.
[4]	Baumann D, Hägele T, Mochayedi J, et al. Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy[J]. Nat Commun, 2020, 11(1):2176.
[5]	王峰，汪刘华，周家杰, 等. 结直肠癌肝转移外科治疗进展[J/CD]. 中华结直肠疾病电子杂志, 2020, 9(4):408-411.
[6]	刘向东，苏松，罗德, 等. 射频消融与手术治疗结直肠癌肝转移疗效的Meta分析[J]. 中国医药导报, 2019, 16(2):89-93, 101.
[7]	杨宏军，王晓斌，孙相华, 等. 冷循环射频消融治疗88例结直肠癌肝转移临床疗效[J].昆明医科大学学报, 2020, 41(6):105-108.
[8]	李广涛，朱晓琳，何红莹, 等. 射频消融与手术切除治疗结直肠癌肝转移的疗效比较[J].中华肝胆外科杂志, 2019, 25(7):487-492.
[9]	Engstrand J, Nilsson H, Strömberg C, et al. Colorectal cancer liver metastases-a population-based study on incidence, management and survival[J]. BMC Cancer, 2018, 18(1):78.
[10]	中华医学会外科学分会胃肠外科学组，中华医学会外科学分会结直肠外科学组，中国抗癌协会大肠癌专业委员会, 等. 中国结直肠癌肝转移诊断和综合治疗指南(V2018)[J/CD]. 中华结直肠疾病电子杂志, 2018, 7(4):302-314.
[11]	李江，王雪峰，蔡晓蓓, 等. 局限性肝段切除联合剜除或射频消融治疗结直肠癌多发肝转移[J]. 中华转移性肿瘤杂志, 2020, 3(1):35-39.
[12]	Violi NV, Duran R, Demartines N, et al. Local recurrence rate in patients with colorectal cancer liver metastasis after wedge resection or percutaneous radiofrequency ablation[J]. Int J Hyperthermia, 2018, 34(7):1020-1028．
[13]	Kaye EA, Cornelis FH, Petre EN, et al. Volumetric 3D assessment of ablation zones after thermal ablation of colorectal liver metastases to improve prediction of local tumor progression[J]. Eur Radiol, 2019, 29(5):2698-2705.
[14]	田耀文，霍婷婷，王东旭, 等. 结直肠癌同时性肝外转移相关临床病理因素分析[J]. 中华肿瘤防治杂志, 2018, 25(2):135-139.
[15]	Pan J, Li X, He Y, et al. Comparison of dexmedetomidine vs. remifentanil combined with sevoflurane during radiofrequency ablation of hepatocellular carcinoma: a randomized controlled trial[J]. Trials, 2019, 20(1):28.
[16]	Hof J, Joosten HJ, Havenga K, et al. Radiofrequency ablation is beneficial in simultaneous treatment of synchronous liver metastases and primary colorectal cancer[J]. PLoS One, 2018, 13(3):e0193385.
[17]	肖永胜，郭磊，叶青海. 结直肠癌肝转移外科治疗[J/CD]. 中华肝脏外科手术学电子杂志, 2019, 8(4):294-296.
[18]	Wang LJ, Zhang ZY, Yan XL, et al. Radiofrequency ablation versus resection for technically resectable colorectal liver metastasis:a propensity score analysis[J]. World J Surg Oncol, 2018, 16(1):207.
[19]	Wang K, Xu D, Yan XL, et al. The impact of primary tumour location in patients undergoing hepatic resection for colorectal liver metastasis[J]. Eur J Surg Oncol, 2018, 44(6):771-777.
[20]	Mao R, Zhao JJ, Bi XY, et al. Resectable recurrent colorectal liver metastasis: can radiofrequency ablation replace repeated metastasectomy?[J]. ANZ J Surg, 2019, 89(7/8):908-913.
[21]	Puijk RS, Ruarus AH, Vroomen LGPH, et al. Colorectal liver metastases: surgery versus thermal ablation (COLLISION) -a phase III single-blind prospective randomized controlled trial[J]. BMC Cancer, 2018, 18(1):821.

项目		RFA组	手术组	统计值	P值
年龄（岁，±s）		74±2	74±2	t=2.732	0.126
BMI（kg/m²，±s）		23.5±2.5	24.2±3.1	t=-1.274	0.293
性别（例）				χ²=0.024	0.877
	男	30	25
	女	18	14
术前合并症（例）				χ²=0.355	0.551
	高血压病	5	4
	冠心病	4	5
	糖尿病	6	4
	慢性阻塞性肺疾病	3	4
	营养不良	6	5
肿瘤位置（例）				χ²=0.264	0.607
	结肠	32	28
	直肠	16	11
发现方式（例）				χ²=0.033	0.857
	同时性	28	22
	异时性	20	17
手术方式（例）				χ²=0.043	0.835
	同期	12	9
	分期	36	30
组织类型（例）				χ²=0.000	0.988
	中、高分化腺癌	27	22
	低分化、粘液腺癌	21	17
转移灶数目（例）				χ²=0.730	0.393
	单发	29	20
	多发	19	19

项目		RFA组	手术组	统计值	P值
年龄（岁，±s）		74±2	74±2	t=2.732	0.126
BMI（kg/m²，±s）		23.5±2.5	24.2±3.1	t=-1.274	0.293
性别（例）				χ²=0.024	0.877
	男	30	25
	女	18	14
术前合并症（例）				χ²=0.355	0.551
	高血压病	5	4
	冠心病	4	5
	糖尿病	6	4
	慢性阻塞性肺疾病	3	4
	营养不良	6	5
肿瘤位置（例）				χ²=0.264	0.607
	结肠	32	28
	直肠	16	11
发现方式（例）				χ²=0.033	0.857
	同时性	28	22
	异时性	20	17
手术方式（例）				χ²=0.043	0.835
	同期	12	9
	分期	36	30
组织类型（例）				χ²=0.000	0.988
	中、高分化腺癌	27	22
	低分化、粘液腺癌	21	17
转移灶数目（例）				χ²=0.730	0.393
	单发	29	20
	多发	19	19

组别	例数	手术时间（min，±s）	术中出血量（ml，±s）	术后住院时间（d，±s）	并发症（例）
组别	例数	手术时间（min，±s）	术中出血量（ml，±s）	术后住院时间（d，±s）	肠梗阻	切口感染	肺部感染	出血
RFA组	48	46±10	29±9	2.5±0.3	0	1	1	1
切除组	39	126±25	301±80	7.3±1.8	2	3	3	1
统计值		t=-5.317	t=-7.233	t=-12.672	χ²=5.124
P值		0.035	0.019	0.007	0.024

组别	例数	手术时间（min，±s）	术中出血量（ml，±s）	术后住院时间（d，±s）	并发症（例）
组别	例数	手术时间（min，±s）	术中出血量（ml，±s）	术后住院时间（d，±s）	肠梗阻	切口感染	肺部感染	出血
RFA组	48	46±10	29±9	2.5±0.3	0	1	1	1
切除组	39	126±25	301±80	7.3±1.8	2	3	3	1
统计值		t=-5.317	t=-7.233	t=-12.672	χ²=5.124
P值		0.035	0.019	0.007	0.024

Please choose a citation manager

Content to export